Connect with us

Spread & Containment

3 Top Growth Stocks to Buy Today

As the world looks towards being on the other end of the COVID-19 pandemic, financial growth is all around us.



As the world increasingly finds itself on the other end of the COVID-19 pandemic, financial growth is all around us. We’re currently riding a four-week winning streak in the market, where the S&P 500 index has gained about 7%.

The U.S. economy is firing on all cylinders, as vaccine distribution is expanding and COVID-19-related business and travel restrictions are being lifted. U.S. GDP is expected to post better than 6% GDP growth in the first quarter and corporate earnings are on track to be up more than 30% from the previous year.

This bullish environment is being supported by government stimulus for individuals and small businesses, in addition to accommodative monetary policy from the Federal Reserve. The Fed has repeatedly said that it will keep short-term interest rates at or near zero, in order to support a full post-pandemic recovery of the U.S. labor market.

On the other hand, there are signs that inflationary pressures are rising. The core producer price index increased by 3.1% in March and businesses are looking to passing along higher input costs to customers. While consumer prices grew just 1.6% excluding food and energy last month, we believe that inflation is the one bogey that can put the brakes on the recent market rally.

That’s because it’s also the Federal Reserve’s job to ensure that inflation does not run rampant. If prices continue to rise, Chair Jerome Powell & Co. could be pressured to increase short-term interest rates sooner, rather than later.

However, investors should not fear the potential for any temporary pullback. A decline in the stock market can lead to excellent opportunities in finding the best growth stocks, and above-average growth is the best antidote for keeping up with inflation.

We’ve found three such stocks to watch today, which we highlight below:

The Best Stocks to Watch Today

Best Technology Stock

Par Technology (PAR)

The company provides technology solutions for two distinct sets of customers: government contracts and the hospitality industry.

The stock recently changed hands around $75.92 and sports a market capitalization of about $1.9 billion. It is a component of the Russell 2000 index, a key proxy for small-cap investors.

While many operators in the hospitality industry have struggled in the past year, Par Technology is still delivering impressive growth. The company increased revenue more than 10% in the fourth quarter of 2020 and also posted 67% bookings growth for its point-of-sale software.

That kind of top-line growth potential has Par on the path toward future profitability. Both empirical data and anecdotal evidence have shown that buying a company on the cusp of generating sustainable profits can boost investment performance.

Par is also looking to augment its growth through acquisitions. Earlier this month, management said that it bought privately-held Punchh, for $500 million of cash and stock. The new business has industry-leading growth in supporting customer loyalty programs and expands the company’s presence in the restaurant industry.

Back in March, Sidoti upgraded the stock from Neutral to Buy. All five active analysts tracked by TipRanks rate Par a Buy and the average price target of $101.75 represents 34% upside potential.

Top technology stock today

In addition, the company carries a Smart Score of 10/10 on TipRanks. This proprietary score utilizes Big Data to rank stocks based on 8 key factors that have historically been a precursor of future outperformance.

par technology top Score

On top of the positive aspects mentioned already, the Smart Score indicates that shares have seen insider buying, in addition to improving sentiment from investors and financial bloggers.

Best Biotech Stock

ImmunityBio (IBRX)

The company develops immunotherapies to combat cancer and infectious diseases. ImmunityBio recently merged with NantKwest and a lead product of the combined company looks to treat bladder cancer.

The stock recently traded around $18.09 and has a market capitalization of about $6.7 billion. It is a component of the S&P Biotech sector SPDR and the Russell 2000 index.

In February, management said that Phase 2/3 clinical trials for its treatment Anktiva showed a complete response. ImmunityBio has received Breakthrough and Fast Track status for the product in this indication. The company is also running a Phase 2 study for lung cancer with Anktiva, in addition to testing its efficacy against pancreatic cancer.

What makes ImmunityBio a top biotech stock is that it has many irons in the fire, offering multiple potential avenues of future growth. The company is currently running more than 20 Phase 2 or Phase 3 trials.

In addition, management said earlier this month that initial Phase 1 data from its COVID-19 vaccine candidate showed a 10-fold increase in T-cell response from a single injection. The next step is a clinical trial with 80 participants that is expected to be fully enrolled in the second quarter.

ImmunityBio is also running early-stage trials for prostate cancer. In March, management said that its developmental vaccine developed T-cell responses for more than one targeted antigen in 94% of patients.

The stock is currently flying under the market’s radar and has just one activist analyst tracked by TipRanks. Joseph Catanzaro has a Buy rating and $25 price target, reflecting 38.2% upside potential.

Analyst recommended best stock

Even though ImmunityBio currently has limited analyst coverage, Catanzaro is considered one of the top names on Wall Street, which adds weight to the call. TipRanks rates him in the top-4% of the more than 7,400 analysts tracked. 

Best Electric Vehicle Stock

Workhorse (WKHS)

The company serves the commercial transportation market and is looking to change the future of vehicle delivery. Workhorse has developed an electric truck that it distributes through Ryder System (R) and even a delivery drone that’s dubbed HorseFly.

The stock recently changed hands around $12.46 and sports a market capitalization of about $1.7 billion. It is a component of the Russell 2000 index.

The company reportedly missed out on a contract with the U.S. Postal Service to deliver electric deliver trucks back in February, although the validity of the deal that was awarded to its competitor is currently under question. Because it’s temporarily down on its luck, Workhorse may well be the best EV stock to buy now.

That’s because the company has a backlog of over 8,000 vehicles. Management has guided that it will deliver 1,800 of those trucks in this year, which is a growth trajectory leading to a consensus analyst estimate that Workhorse can generate over $300 million of revenue in 2022.

The company also has a hidden asset in that it’s the second largest investor in electric pickup truck manufacturer, Lordstown Motors (RIDE). Workhorse owns 9.3% of Lordstown, a stake that’s currently worth about $160 million.

In addition, Wall Street sees value in the stock. Earlier this month, B. Riley initiated coverage of the company with a Buy rating, stating:

“We believe Workhorse has the potential to gain early footing with key customers as it ramps up production and sales this year. The company will be beating to market most of the electric competition focused on the delivery space by quarters or years with its C-Series ramp expected this year, and we believe the larger size cargo offers differentiation in the space relative to the smaller-volume vans coming from the large auto OEMs and upstarts.”

Of the seven active analysts tracked by TipRanks, the average price target of $21.20 represents 70.1% upside potential.

Top EV Stock today

Like Par Technology, Workhorse also has a Smart Score of 10/10. On top of the positive aspects mentioned already, the Smart Score indicates that Workhorse has seen improving sentiment from hedge funds and financial bloggers.

Focus on Growth

Investors are always looking for growth; but it’s more important than ever, when stocks are near record highs and inflationary pressures are rising. With U.S. GDP approaching double-digit growth in 2021 and the Federal Reserve likely to keep short-term interest rates low for the next several quarters, these three names are among the best stocks to watch today.

Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

The post 3 Top Growth Stocks to Buy Today appeared first on TipRanks Financial Blog.

Read More

Continue Reading

Spread & Containment

China Suspends Travel, Ramps Up Testing As Delta Outbreak Hits Wuhan

China Suspends Travel, Ramps Up Testing As Delta Outbreak Hits Wuhan

China’s worst outbreak since COVID first emerged in the city of Wuhan has continued to spread, prompting authorities to intensify their efforts to crush the delta-driven…



China Suspends Travel, Ramps Up Testing As Delta Outbreak Hits Wuhan

China's worst outbreak since COVID first emerged in the city of Wuhan has continued to spread, prompting authorities to intensify their efforts to crush the delta-driven outbreak. However, as the virus continues to elude their grasp, it's looking increasingly likely that Beijing's "zero tolerance" approach might hamstring economic growth, as analysts from Goldman Sachs warned in a recent note to clients.

More than 2 dozen cities have counted more than 300 cases over the past few weeks as the number of cases has quickly multiplied. China now has 144 medium- and high-risk areas - the most since the initial outbreak in early 2020, according to the National Health Commission.

By Monday, all of China's 31 provincial-level jurisdictions had issued notices by Monday advising people not to travel domestically. Some provincial governments singled out only medium- and high-risk regions, while others asked people to avoid all inter-provincial travel. According to the SCMP, Beijing's "zero-tolerance" approach to fighting COVID, which remains minimal compared with China's vast population, has "scared away" the tourists.

China reported 71 new COVID cases from local transmission on Wednesday, more than half of them in coastal Jiangsu province near the epicenter of Nanjiang, AP reported.

The CCP has decided to expand travel restrictions on Wednesday: ride-hailing services and public transit have been suspended in all medium- to high-risk areas. Immigration authorities have promised to "strictly restrict non-urgent, unnecessary cross-boarder travel" including restricting the issuing of passports for Chinese citizens. To try and stifle the virus before it has an opportunity to take hold, the city ordered millions of residents to undergo mandatory testing, leading to lines forming across the city. The city has also closed 17 bus lines and a handful of subway stations. Cases have been confirmed in 17 provinces and some two dozen cities, including Wuhan, which reported a handful of cases this week, per CNN.

Fears of another crushing lockdown - many Wuhan residents still have PTSD from the 70-day+ lockdown in the city that was used to crush the original outbreak, at a tremendous cost to the city's residents mental and physical health. Videos and photos shared on social media have shown empty shelves and long lines at supermarkets, as residents scramble to stock up on supplies.

"Seeing Wuhan people panic buying at supermarkets makes me feel sad. Only those who have experienced it understand how terrible it is, (we) dread a return to the days of staying at home and not knowing where the next meal is," said one Wuhan resident on Weibo.

The present outbreak began a little over a week ago in Nanjing, a city in Jiangsu province in eastern China, where nine airport cleaners were found to be infected on July 20 during a routine test. Chinese authorities have blamed the cluster on workers from Russia, who arrived at the Nanjing Lukou International Airport on July 10.

"It is believed that the cleaners did not strictly follow anti-epidemic guidelines after cleaning Flight CA910 and contracted the virus as a result. The infection further spread to other colleagues, who are also responsible for cleaning and transporting garbage on both international and domestic flights," reported state news agency Xinhua.

Given the provenance of the latest outbreak, Beijing has committed to ramp up testing of transport workers around the country. Workers at ports and borders considered high risk will be tested for the virus every other day said Li Huaqiang, a senior official with Ministry of Transport.

Earlier this week, another COVID-19 hotspot was identified in the city of Zhangjiajie, near a scenic area famous for sandstone cliffs, caves, forests and waterfalls.

Despite only confirming some 19 cases over the past week, the city ordered residential communities sealed Sunday, preventing people from leaving their homes. In a subsequent order on Tuesday, officials said no residents, and no tourists, would be allowed to leave the city. On Wednesday, the city government's Communist Party disciplinary committee issued a list of local officials who "had a negative impact" on pandemic prevention and control work who would be punished.

Far higher numbers were reported in Yangzhou, a city next to Nanjing, which has recorded 126 cases as of Tuesday. As a result, all cross-city ferry services, water tours were suspended in eastern Yangzhou on Wednesday.

But most alarmingly, the outbreak has already touched Beijing, eve though it's thousands of miles removed from the epicenter in Nanjiang. On Wednesday, 7 cases were confirmed in the capital city, prompting authorities to lock down two residential compounds.

As of this wee, China has doled out more than 1.71 billion vaccine doses to its population of 1.4 billion. Officials say 40% of the population is fully vaccinated, but the outbreak is also raising questions about the efficacy of those vaccines.

Tyler Durden Wed, 08/04/2021 - 18:00

Read More

Continue Reading


Broward County Public Schools “Pause” Proposed Mask Mandate After DeSantis Threatens To Cut Funding

Broward County Public Schools "Pause" Proposed Mask Mandate After DeSantis Threatens To Cut Funding

Update: Broward County schools on Aug. 3 again changed course on whether to comply with or defy an executive order by Republican Gov. Ron…



Broward County Public Schools "Pause" Proposed Mask Mandate After DeSantis Threatens To Cut Funding

Update: Broward County schools on Aug. 3 again changed course on whether to comply with or defy an executive order by Republican Gov. Ron DeSantis which prohibited schools from imposing mask mandates on students.

In a written statement to The Epoch Times, the school board has not changed its policy but “paused it.”

“In light of the governor’s executive order, the district is awaiting further guidance before rendering a decision on the mask mandate for the upcoming school year. At this time, the district’s face covering policy, which requires the use of masks in district schools and facilities, remains in place.”

The School Board plans to discuss next steps at a special meeting on August 10.

Dr. Vickie Cartwright, interim superintendent of Broward County schools is looking into the executive order further.

“The school board is reviewing information and looking for language from our executive rules as a result of the governor’s executive order,” Cartwright said in a video statement.

On July 30, the governor signed an executive order that protects parents’ right to make decisions regarding the masking of their children as a means of protecting them from COVID-19. A month earlier, he signed a bill that protected the parents’ “fundamental right” to make decisions for the upbringing, education, health care, or mental health of their minor children.

“Many Florida schoolchildren have suffered under forced masking policies, and it is prudent to protect the ability of parents to make decisions regarding the wearing of masks by their children,” DeSantis said.

*  *  *

As we detailed earlier, Florida Governor Ron DeSantis has had enough of the Covid hysteria.

Aside from going on record and calling the lockdowns a "huge mistake" back in April of his year, DeSantis has done everything he can to try and turn over the power in his state to its citizens, and away from the government.

The latest example of this comes this week, where DeSantis stood down Florida's second largest school district that was attempting to impose a mask mandate. In response, DeSantis threatened to withhold funding from the district. 

"Broward County Public Schools announced last week that it would require mask use after the CDC issued new guidance recommending universal indoor masking for all teachers, staff, students and visitors to K-12 schools this incoming school year, regardless of vaccination status," Axios reported this week.

DeSantis had issued an executive order last Friday barring schools from requiring masks when school re-opens next month. His order read that "if the State Board of Education determines that a district school board is unwilling or unable to comply with the law, the State Board shall have the authority to, among other things, withhold the transfer of state funds, discretionary grant funds ... and declare the school district ineligible for competitive grants."

And that's exactly what DeSantis threatened to do before Broward County Public Schools backed down, releasing a statement on Monday that said: "Broward County Public Schools intends to comply with the governor's latest executive order."

The statement continued: "Safety remains our highest priority. The district will advocate for all eligible students and staff to receive vaccines and strongly encourage masks to be worn by everyone in schools."

DeSantis also spoke at a press conference this week, stating: “Even among a lot of positive tests, you are seeing much less mortality that you did year-over-year. Would I rather have 5,000 cases among 20-year-olds or 500 cases among seniors? I would rather have the younger.”

“We are not shutting down. We are going to have schools open. We are protecting every Floridian’s job in this state. We are protecting people’s small businesses. These interventions have failed time and time again throughout this pandemic, not just in the United States but abroad.”

As we noted back in April, DeSantis told The Epoch Times that the lockdowns were a “huge mistake,” including in his own state.

“We wanted to mitigate the damage. Now, in hindsight, the 15 days to slow the spread and the 30—it didn’t work,” DeSantis said.

“We shouldn’t have gone down that road.”

Florida’s lockdown order was notably less strict than some of the stay-at-home measures imposed in other states. Recreational activities like walking, biking, golf, and beachgoing were exempted while essential businesses were broadly defined.

“Our economy kept going,” DeSantis said. “It was much different than what you saw in some of those lockdown states.”

DeSantis has also opposed vaccine passports in Florida. 

Tyler Durden Wed, 08/04/2021 - 22:40

Read More

Continue Reading

Spread & Containment

‘For $1/Day’… Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

‘For $1/Day’… Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

A double-blind Israeli study has concluded that Ivermectin, an inexpensive anti-parasitic widely used since 1981, reduces both…



'For $1/Day'... Double-Blind Ivermectin Study Reveals COVID Patients Recover More Quickly, Are Less Infectious

A double-blind Israeli study has concluded that Ivermectin, an inexpensive anti-parasitic widely used since 1981, reduces both the duration and infectiousness of Covid-19, according to the Jerusalem Post.

The study, conducted by Prof. Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center in Tel Hashomer, looked at some 89 eligible volunteers over the age of 18 who had tested positive for coronavirus, and were living in state-run Covid-19 hotels. After being divided into two groups, 50% received ivermectin, and 50% received a placebo. Each patient was given the drug for three days in a row, an hour before eating.

83% of participants were symptomatic at recruitment. 13.5% of patients had comorbidities of cardiovascular disease, diabetes, chronic respiratory disease, hypertension or cancer. The median age of the patients was 35, ranging from 20 to 71-years-old.


Treatment was discontinued on the third day, and patients were monitored every two days thereafter. By day six, 72% of those treated with ivermectin tested negative for the virus, vs. 50% of those who received the placebo. Meanwhile, just 13% of ivermectin patients were able to infect others after six days compared to 50% of the placebo group - nearly four times as many.


Three patients in the placebo group were admitted to hospitals for respiratory symptoms, while one ivermectin patient was hospitalized for shortness of breath the day the study began - only to be discharged a day later and "sent back to the hotel in good condition," according to the study.

"Our study shows first and foremost that ivermectin has antiviral activity," said Schwartz, adding "It also shows that there is almost a 100% chance that a person will be noninfectious in four to six days, which could lead to shortening isolation time for these people. This could have a huge economic and social impact."

The study, which appeared on the MedRxiv preprint server and has not yet been peer-reviewed. That said, Schwartz pointed out that similar studies - 'though not all of them conducted to the same double-blind and placebo standards as his' - also showed favorable results for the drug.

Ivermectin is incredibly cheap due to its widespread use across the world to treat malaria, scabies, lice and other parasitic infections. In Bangladesh, the cost of ivermectin is around $0.60 to $1.80 for a five-day course, according to the report. In Israel, it costs up to $10 per day.

While Schwartz's study showed efficacy among those who had already tested positive, it didn't determine whether ivermectin is an effective prophylactic which could prevent one from contracting Covid-19, nor does it show whether it reduces chances of hospitalization - however Schwartz noted that other studies have shown such evidence.

For example, the study published earlier this year in the American Journal of Therapeutics highlighted that “a review by the Front Line COVID-19 Critical Care Alliance summarized findings from 27 studies on the effects of ivermectin for the prevention and treatment of COVID-19 infection, concluding that ivermectin ‘demonstrates a strong signal of therapeutic efficacy’ against COVID-19.”

“Another recent review found that ivermectin reduced deaths by 75%,” the report said. -Jerusalem Post

As the Post notes, Ivermectin has been actively opposed as a Covid treatment by the World Health Organization, the FDA, and pharmaceutical companies.

The “FDA has not approved ivermectin for use in treating or preventing COVID-19 in humans,” it said.

“Ivermectin tablets are approved at very specific doses for some parasitic worms, and there are topical (on the skin) formulations for head lice and skin conditions like rosacea. Ivermectin is not an antiviral (a drug for treating viruses). Taking large doses of this drug is dangerous and can cause serious harm.”

Mere discussion of the drug has resulted in big-tech censoring or deplatforming thought leaders in collaboration with the Biden administration.

Meanwhile, Merck Co. - which manufactured the drug in the 1980s, has come out big against the use of ivermectin to treat Covid-19. In February, the company's website read: "Company scientists continue to carefully examine the findings of all available and emerging studies of Ivermectin for the treatment of COVID-19 for evidence of efficacy and safety. It is important to note that, to date, our analysis has identified no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies; no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease, and a concerning lack of safety data in the majority of studies."

As the Post points out - Merck has not launched a single study of its own on ivermectin.

"You would think Merck would be happy to hear that ivermectin might be helpful to corona patients and try to study it, but they are most loudly declaring the drug should not be used," said Schwartz.

"A billion people took it. They gave it to them. It’s a real shame."

In closing, the research team writes that "Developing new medications can take years; therefore, identifying existing drugs that can be re-purposed against COVID-19 [and] that already have an established safety profile through decades of use could play a critical role in suppressing or even ending the SARS-CoV-2 pandemic."

"Using re-purposed medications may be especially important because it could take months, possibly years, for much of the world’s population to get vaccinated, particularly among low- to middle-income populations."

Tyler Durden Wed, 08/04/2021 - 18:55

Read More

Continue Reading